Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

<p>Abstract</p> <p>Background</p> <p>To improve the efficacy of first-line therapy for advanced non-small cell lung cancer (NSCLC), additional maintenance chemotherapy may be given after initial induction chemotherapy in patients who did not progress during the initial...

Full description

Bibliographic Details
Main Authors: Jaime Jesús, Vaury Alexandra, Altug Sedat, Paz-Ares Luis G, Russo Francesca, Visseren-Grul Carla
Format: Article
Language:English
Published: BMC 2010-03-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/85

Similar Items

Similar Items